Our leadership team possesses deep and diverse industry knowledge, a passion for science and a shared commitment to help transform lives. Made up of our founding scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, we consistently push the boundaries of scientific excellence and discovery.
Zoran Berkovic joined Regeneron in 2017 and is senior vice president, financial planning & analysis, where he has grown the scope of the group and fostered a culture of accountability. He previously served as the regional CFO for Japan, Australia and New Zealand at Mylan, as well as other roles, and he worked at Cephalon in financial roles. Mr. Berkovic earned his B.S. and BBA in finance and economics abroad and his MBA at Temple University.
Maya Bermingham, J.D., joined Regeneron in 2015 and serves as senior vice president, public policy and government affairs. Ms. Bermingham and her Washington, DC-based team play a critical role in helping Regeneron shape and maintain its industry-leading reputation among governmental stakeholders. In 2020, Ms. Bermingham stepped forward to also serve as the company’s interim head of diversity, equity and inclusion (DE&I). Prior to joining Regeneron, Ms. Bermingham held roles of increasing responsibility at PhRMA over a 12 year tenure, following earlier positions at legal firms, and work for Senator Moynihan and the Senate Finance Committee. She received her B.A. from Harvard University and her J.D. from New York University.
Leonard (Len) Brooks joined Regeneron in 2013 and serves as senior vice president, treasurer. Mr. Brooks leads a team responsible for optimizing liquidity and use of capital resources, safeguarding Regeneron’s cash and investment portfolio, corporate risk management and maintaining strong relationships with financial institutions, insurance providers and rating agencies. Prior to joining Regeneron, Mr. Brooks worked in public accounting at Deloitte before moving to treasury, where he held various positions of increasing responsibility at both mid- and large-sized companies, including Wyeth, Medco Health Solutions, Reliant Pharmaceuticals, The Children’s Place and Hayward Industries. Mr. Brooks received both a B.S. and an MBA from Rutgers University.
John Calabro joined Regeneron in 2005 and serves as senior vice president, internal audit. Mr. Calabro leads a team responsible for providing independent and objective assurance and consulting by bringing a systematic, disciplined approach to evaluating and improving the effectiveness of Regeneron’s risk management, control and governance processes. Prior to joining Regeneron, Mr. Calabro spent 18 years at UST, Inc., where he held positions of increasing responsibility within internal audit, ultimately serving as director of internal. He also previously served within the internal audit teams at Phillip Morris, General Foods and Bowater, Inc. Mr. Calabro received a B.S. from the University of Connecticut.
Christina Chan joined Regeneron in 2021 and serves as senior vice president, corporate affairs, leading a multidisciplinary team responsible for external & internal communication, patient advocacy, corporate responsibility, ESG strategy & reporting, and social impact. Before joining Regeneron, Christina served as vice president, global finance communication at Johnson & Johnson (J&J). Prior to that, she led executive communication and thought leadership for J&J’s Chairman & CEO and oversaw communication for J&J’s diversity, equity & inclusion programs and heritage platforms. She previously led communication for the cardiovascular & metabolism therapeutic area and global commercial strategy organization at Janssen, J&J’s pharmaceutical division. Prior to joining J&J, Christina worked in financial and corporate communications for Biogen and at Boehringer Ingelheim in various pharmaceutical sales and communications roles. Christina holds an MBA in finance and strategy from the Stern School of Business at New York University and a B.A. in international relations and Chinese from Tufts University.
Matthew Everett joined Regeneron in 2023 and serves as senior vice president, strategic sourcing and procurement. Mr. Everett leads a team responsible for Regeneron’s supplier engagements, accountable to accelerate innovation, business process efficiency and return on investment across these relationships and in alignment with corporate ESG priorities. Most recently, Mr. Everett served as vice president, global procurement at GSK. Mr. Everett previously worked at Allergan, Forest Laboratories, Flex and Lucent Technologies, where he led diverse procurement and supply chain functions. Mr. Everett earned his M.S. from Columbia University, MBA from Fordham University and BBA from the University of San Diego.
Chris Fenimore joined Regeneron in 2003 and, as the current head of accounting and controller, has global responsibility for SEC reporting, accounting and accounting operations, and internal control over financial reporting, administration of financial systems, accounts payable and payroll. Prior to his current role, he served as Regeneron’s vice president of financial planning, and prior to joining Regeneron, he was vice president of finance at Mojave Therapeutics, Inc. He has prior experience in healthcare industry-focused venture capital and investment banking roles, as well as serving as an audit senior at KPMG. Mr. Fenimore holds an M.A. in biotechnology from Columbia University, an MBA in professional accounting from Rutgers Business School and a B.A. in economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the state of New York.
Nouhad Husseini joined Regeneron in 2011 and is head of business development, overseeing the company’s efforts to execute new strategic collaborations and licensing agreements. He has nearly 20 years of experience in the biopharmaceutical industry, where he has held a variety of strategic, business development and finance roles, including in Genentech’s Business Development and Corporate Finance departments and in investment banking and equity research at Morgan Stanley and Robertson Stephens. Mr. Husseini received his undergraduate degree in molecular biology from Princeton University and MBA from the Wharton School at University of Pennsylvania.
Robert E. Landry joined Regeneron in 2013 and serves as executive vice president, finance and chief financial officer. Prior to joining Regeneron, Mr. Landry served as senior vice president and treasurer of Pfizer Inc. Mr. Landry also held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in accounting from the University of Notre Dame.
Joseph J. LaRosa joined Regeneron in 2011 and is currently executive vice president, general counsel and secretary. Prior to joining Regeneron, Mr. LaRosa was senior vice president, general counsel and secretary at Nycomed U.S., Inc. He also previously served as vice president, global compliance and legal affairs at Avon Products, Inc., and held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as vice president, legal affairs, and a member of the operations management Team. Mr. LaRosa received his J.D. degree from New York University.
Melissa Lozner, J.D., joined Regeneron in 2022 and serves as senior vice president, chief compliance officer. Ms. Lozner oversees all aspects of Regeneron’s corporate compliance program. Since joining the company, she has focused her efforts on evolving the compliance program and organizational structure to better support global expansion, as well as creating a new compliance risk navigation & advisory services group to better integrate compliance across the business. Prior to joining Regeneron, Ms. Lozner served as chief compliance officer and special counsel at Rafael Holdings, where she was responsible for building a compliance program for a start-up biotechnology company. She also held a number of roles within Novartis Oncology, including head of U.S. ethics, risk & compliance, head of global integrity & compliance, ad interim, and senior legal counsel. Prior to joining the industry, Ms. Lozner was a litigation attorney and served as a law clerk for Hon. Boyce F. Martin, Jr., Chief Judge Emeritus, U.S. Court of Appeals for the Sixth Circuit. Ms. Lozner earned a B.S. from Cornell University and a J.D. from Boston University School of Law.
Marion McCourt joined Regeneron in 2018 and serves as executive vice president and head of the commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a clinical-stage biopharmaceutical company, where she was president and chief operating officer. She served as chief operating officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including vice president in U.S. commercial operations and vice president and general manager responsible for the company’s bone health and primary care business unit. Ms. McCourt began her career and spent 12 years at AstraZeneca, ultimately becoming chief operating officer for AstraZeneca U.S. She received her B.S. from Lafayette College.
Bob McCowan is senior vice president and chief information officer at Regeneron. With over 30 years global experience, Mr. McCowan leads the company’s IT organization and is responsible for global IT strategy supporting research, commercial, cyber security and enterprise operations. He has driven an enhanced company focus on big data, innovation and strategic IT investments that support Regeneron’s mission. Mr. McCowan previously worked at international organizations including Amgen, Artemis International, Computer Science Corporation and Lockheed. He earned his MBA with the UK Open University and holds a degree in electrical engineering.
Gonzalo Merino, Ph.D., J.D., joined Regeneron in 2013 and now serves as senior vice president and chief intellectual property counsel. He is responsible for protecting Regeneron’s intellectual property, including by developing and implementing a comprehensive global IP strategy. Prior to joining Regeneron, Dr. Merino was an associate general counsel at Columbia University and a patent attorney at Bryan Cave LLP in New York City. He obtained his J.D. from Columbia University Law School, where he was a Harlan Fisk Stone Scholar, and his Ph.D. from the Integrated Program in Cellular, Molecular and Biophysical Studies at the Columbia University Graduate School of Arts and Sciences, where he received the Richard C. Parker Award for Outstanding and Innovative Research and a minority pre-doctoral fellowship award.
Richard (Rich) O’Neal joined Regeneron in 2018 and is the senior vice president of market access. Prior to Regeneron, Mr. O’Neal held roles at Axovant, Amgen and Express Scripts. He earned his R.Ph. from the University of Health Science and Pharmacy and his MBA from Lindenwood University.
Sally A. Paull joined Regeneron in 2016 and now serves as executive vice president, human resources. She was previously executive vice president, chief human resources oﬃcer at Inova Health System. Prior to Inova, Ms. Paull was senior vice president, chief human resources oﬃcer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her B.S. from the United States Air Force Academy and her M.A. in International Relations from the University of Delaware.
Smita Pillai joined Regeneron as our first chief diversity, equity and inclusion (DEI) officer in 2021. Ms. Pillai has an accomplished global DE&I career spanning life sciences, technology, financial services and media sectors. Most recently she was VP, global head of DE&I at Zendesk. Prior to that she was chief diversity officer for Dow Jones, including its flagship brand, The Wall Street Journal. Before that, she has led global marketing research, corporate strategy and DE&I efforts at Fortune 50 companies such as Prudential Financial, Johnson & Johnson and ACNielsen. A certified DE&I professional, Ms. Pillai received her BBA from KS School of Management and her MBA from Symbiosis International Business School, India.
Alessandra Ravetti, J.D., joined Regeneron in 2012 and serves as senior vice president, associate general counsel. Ms. Ravetti leads the Global Pharmaceutical Legal Operations team, a multidisciplinary team providing legal advice on the clinical development and commercialization of Regeneron’s products, including advice on R&D, regulatory matters, market access, product launches, lifecycle planning, and healthcare law compliance. Prior to joining Regeneron, Ms. Ravetti spent 10 years at Pfizer in various positions of increasing responsibility, and she was previously an Associate at the law firm of Sullivan and Cromwell. She received a J.D. from New York Law School, an M.A. from Boston College and a B.A. from Binghamton University.
Kerry Reinertsen, Ph.D., joined Regeneron in 2011 and serves as senior vice president of strategic alliances. Prior to joining Regeneron, she was chief business officer of Constellation Pharmaceuticals. Before this, Dr. Reinertsen served as the vice president of corporate development at Vertex Pharmaceuticals. Dr. Reinertsen started her biotech career at Millennium Pharmaceuticals (now Takeda Oncology) where she held positions of increasing responsibility in business development. Dr. Reinertsen received her Ph.D. in biological chemistry and molecular pharmacology from Harvard University and her Sc.B. in molecular biology and A.B. in economics from Brown University.
David Snow joined Regeneron in 2020 and is senior vice president and global head of the Dupixent® (dupilumab) franchise. Prior to working at Regeneron, Mr. Snow built his expertise at various pharmaceutical and healthcare companies including AstraZeneca, Bristol Myers Squibb, Eloxx Pharmaceuticals and Radius Health. He received his B.S. in marketing at Auburn University and his MBA at New York University.
Mark Volpe, J.D., joined Regeneron in 2012 and is senior vice president, tax. He previously held roles on the tax teams at Arthur Anderson, Ernst & Young, and Diageo, and he currently serves as secretary and member of the board of trustees at Intensive Therapeutics, a 501c3 non-profit organization that provides therapy services to children with special needs. Mr. Volpe received an A.S. in accounting from Suffolk County Community College, followed by a B.A. at the State University of New York at Albany and a J.D. at Saint John’s University.
Research and Development Leaders
Bola Akinlade, M.D., FACP, joined Regeneron in 2015 and serves as senior vice president, clinical development for Regeneron’s immunology and inflammation (I&I) portfolio. Prior to Regeneron, Dr. Akinlade held medical director roles of increasing seniority at Astellas Pharma and Abbott Laboratories (now AbbVie). He earned his B.S. and M.D. in Nigeria before moving to the U.S. for his residency at the University of Connecticut. He received his MBA from Northwestern University Kellogg School of Management.
Hanne Bak, Ph.D., joined Regeneron in 2004 and serves as senior vice president, preclinical manufacturing and process development (PMPD). She started her career at Regeneron as a research engineer working in the purification development group within PMPD and has subsequently held roles of increasing responsibility. Dr. Bak received her B.S., M.S. and Ph.D. in chemical engineering from Danmarks Tekniske Universitet (Technical University of Denmark).
Aris Baras, M.D., joined Regeneron in 2011 and helped found the Regeneron Genetics Center (RGC™), where he now serves as senior vice president. Previously, he held roles and responsibilities at Regeneron across R&D and business development. Prior to joining Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his B.S., MBA and M.D. from Duke University.
Ned Braunstein, M.D., joined Regeneron in 2009, and serves as executive vice president, regulatory affairs and global patient safety. Prior to joining Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then associate professor of medicine, and at Merck & Co., Inc. for nine years in positions of increasing responsibility in clinical research, regulatory aﬀairs and global human health. Dr. Braunstein received his B.S. in medicine and his M.D. from Northwestern University.
Gang Chen, Ph.D., is the head of protein expression sciences (PES) in his role as senior vice president. Having joined the company in 1999, Dr. Chen has held scientific roles of increasing responsibility over his 23 years with Regeneron. He received his B.S. in biology from the University of Science and Technology of China and his Ph.D. in cell biology from the University of Washington.
Thomas DiCioccio, Ph.D., joined Regeneron in 2010 and serves as senior vice president, pharmacometrics. Dr. DiCioccio leads a team for four integrated functions: Preclinical & Translation PK/PD, and clinical and quantitative pharmacology with supporting efforts from a group of data scientists. Collectively, through integration of pharmacology with modeling and other quantitative methods, the functions within pharmacometrics play a central role in dose selection from first-in-human studies through global market applications as well as post-approval activities. The pharmacometric functions are also responsible for the associated documentation needed to support clinical protocols, as well as the nonclinical PK and clinical pharmacology summaries for the global regulatory filings. Prior to joining Regeneron, Dr. DiCioccio spent 14 years with a biotechnology start-up, after previously working with Lederle Laboratories for 14 years. Dr. DiCioccio earned an B.S. from SUNY Stony Brook, a M.S. at New York Medical College and a Ph.D. from Saint John’s University.
Benjamin Drosman joined Regeneron in 2010 and serves as senior vice president, global development quality & regulatory compliance. Mr. Drosman leads a team that strategically aligns various quality functions and oversees an integrated quality management system (QMS). In addition, his team oversees regulatory functions including labeling and advertising/promotion and compliance. Prior to joining Regeneron, Mr. Drosman worked at Pfizer for 12 years holding various positions of increasing responsibility in pharmacovigilance, quality assurance and regulatory strategy. Mr. Drosman earned a B.S. in pharmacy from Long Island University and an MBA from the University of Phoenix.
Gregory Geba, M.D., Ph.D., joined Regeneron in 2013 and serves as senior vice president of the global development scientific council, a group that provides senior scientific input to Regeneron’s therapeutic portfolio of programs. He is a physician-scientist with decades of experience in design, execution and analysis of clinical trials. Previously, Dr. Geba worked at Sanofi, AstraZeneca, Novartis, Merck and Yale University as an assistant professor of medicine. He received his B.A. in biology from Brown University, M.D. from the University of Navarra, completed a fellowship in immunology/pulmonary and critical care at Yale University, received an MPH. in epidemiology from The Johns Hopkins University, and his Ph.D. in molecular toxicology from Columbia University.
Gary Herman, M.D., joined Regeneron in 2015 and leads the early clinical development and experimental sciences (ECDES) function. Previously, he served in roles of increasing responsibility at Merck, most recently as the vice president and head, early stage development. From 2008 to 2015, Dr. Herman was one of only three pharmaceutical industry members on the Executive Committee of the Biomarkers Consortium, a program within the Foundation for the National Institutes of Health. Prior to that, Dr. Herman completed his residency and postdoctoral training at University of California, San Francisco and was an assistant professor there before joining industry. He received his B.S. in biochemistry and cell biology from the University of California, San Diego, and his M.D. from Harvard Medical School.
Boaz Hirshberg, M.D., MBA, joined Regeneron in 2021 and serves as senior vice president, clinical sciences general medicine, leading strategic program direction and late stage clinical development for a broad range of therapeutic areas including ophthalmology, cardiovascular and metabolic, pain and neurology, and infectious and rare diseases. Before joining Regeneron, Dr. Hirshberg was executive vice president, chief medical officer and head of global development at BOL Pharma, a biotech developing medical cannabis therapeutics, where he directed preclinical and clinical development, regulatory, pharmacovigilance and medical affairs. Prior to BOL, he spent 12 years at AstraZeneca/MedImmune in roles of increasing responsibility, ultimately building and overseeing the cardiovascular renal and metabolism clinical therapeutic area at MedImmune. Dr. Hirshberg completed his undergraduate and medical degrees at the Hebrew University and is board certified in internal medicine, following his residency at the Hadassah Medical center in Jerusalem. He received his MBA in health care administration from Wilmington University.
Diana Hughes, MBBS, joined Regeneron in 2019 and serves as senior vice president, global patient safety. Under Dr. Hughes’ leadership, Regeneron’s Pharmacovigilance and Risk Management function has evolved to global patient safety (GPS), and she has reorganized the safety function in a scalable manner, integrating science, operations and technology advancement to support Regeneron’s global pipeline, while aligning with the external regulatory landscape. Dr. Hughes worked for Sunovion Pharmaceuticals, FORUM Pharmaceuticals, and spent 14 years at Pfizer, where she held various roles of increasing responsibility. Before joining the pharmaceutical industry, Dr. Hughes worked as a medical practitioner in the UK and U.S. Dr. Hughes earned a medical degree (MBBS) from The Royal Free Hospital and School of Medicine, London University, and an M.Sc. from Hibernia College.
Bari Kowal joined Regeneron in 2015 and became head of global clinical operations in 2017. She currently serves as senior vice president, development operations and portfolio management and is responsible for clinical trial strategy and execution, along with overseeing our development shared services functions. She was previously at Pfizer where she held the positions of vice president, business operations and analytics, and, prior to that, vice president, strategic alliance and development operations lead. Ms. Kowal also served as vice president, clinical operations, on the clinical research organization side of the industry at a number of biotech organizations in a variety of clinical research roles early in her career. She holds a B.S. in biology from the State University of New York at Binghamton and an M.S. in neuroscience from New York University.
Christos Kyratsous, Ph.D., joined Regeneron in 2011 and is the senior vice president of research. He leads the development of our next-generation genetic therapeutics platforms and is the head of the infectious diseases therapeutic focus area. Dr. Kyratsous previously worked at the Howard Hughes Medical Institute and was a postdoctoral fellow at New York University. He received his B.S. from the Aristotle University of Thessaloniki in Greece and then received his Ph.D. in microbiology at Columbia University.
Johnathan M. Lancaster, M.D., Ph.D., joined Regeneron in 2019 as a vice president and now serves as SVP and head of global medical affairs. Prior to joining Regeneron, Dr. Lancaster served as chief medical officer at Myriad Genetics, Inc., following more than a decade in academics at Moffitt Comprehensive Cancer Center in Tampa as a gynecologic oncologist, molecular genetics researcher, and ultimately President of the Moffitt Medical Group Corporation. Dr. Lancaster received his BSc in pharmacology and his M.D. and Ph.D. from the University of Wales in the UK. He received post graduate clinical training in OBGYN and gynecologic oncology at the University of Cambridge and Duke University Medical Center.
John Lin, M.D., Ph.D., joined Regeneron in 2016 and oversees the preclinical bispecific antibody research work in research and development across all disease areas. Previously, he worked at Pfizer for 10 years focusing on research and early development of biologics, and before that he worked at Rinat Neuroscience Corporation after completing his postdoctoral fellowship at Genentech. Dr. Lin received his M.D. from National Taiwan University and his Ph.D. from Harvard University.
Israel Lowy, M.D., Ph.D., joined Regeneron in 2010 as vice president, and now serves as senior vice president, translational and clinical sciences, oncology. He is a primary architect of Regeneron’s cancer immunotherapy program. Prior to joining Regeneron, Dr. Lowy was at Medarex for eight years. Before that, he was assistant professor of medicine and microbiology at Mount Sinai School of Medicine. Dr. Lowy is a licensed physician and has been board certified in internal medicine and infectious diseases. He received his A.B. in biochemical sciences from Princeton University and his M.D., Ph.D. in biochemistry and molecular biophysics from Columbia University.
Lynn Macdonald, Ph.D., joined Regeneron in 1999 and serves as senior vice president, research. Dr. Macdonald is responsible for heading the VelocImmune-NEXT technology development group, neuroscience group, molecular profiling & data sciences group, and DNA core & Automation group. She has been a key contributor to developing Regeneron’s groundbreaking VelociSuite® of genomics technologies, including playing a critical role in developing VelociGene®, and subsequently working as part of a team that developed the VelocImmune® Mouse. Prior to joining Regeneron, Dr. Macdonald worked for Cadus Pharmaceuticals after completing a post-doctoral fellowship at Columbia University. She earned a B.S. from the University of Rochester and a Ph.D. from State University of New York.
Lori Morton, Ph.D., joined Regeneron in 2002 and serves as senior vice president, research. During her tenure, Dr. Morton has established cardiovascular, renal and fibrosis research at Regeneron. In her role, Dr. Morton has led the discovery and development of a highly innovative and diverse portfolio across disease areas. In addition to a robust portfolio of antibody therapeutics, she has been a company leader in the application of novel nucleotide and gene therapies. As well as serving as a R&D leader, Dr. Morton also sponsors the Women in Industry, Science & Engineering at Regeneron (WISER) employee resource group. Prior to joining Regeneron, Dr. Morton completed post-doctoral fellowships at Pfizer and Sloan Kettering Cancer Center. Dr. Morton earned a B.S. from Douglass College of Rutgers University and a Ph.D. from the University of North Carolina at Chapel Hill.
Andrew Murphy, Ph.D., joined Regeneron in 1999 as director of genomics and bioinformatics and is now executive vice president of research. In his time at the company, he has led the gene discovery and bioinformatics and target discovery groups. Dr. Murphy is a co-inventor of several of Regeneron's key technologies, VelociGene® and VelocImmune®, and continues to lead several technology centers and therapeutic focus areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his B.S. in molecular biology at the University of Wisconsin, and his Ph.D. in human genetics from Columbia University, College of Physicians and Surgeons.
William Olson, Ph.D., joined Regeneron in 2013 as vice president and now serves as senior vice president of therapeutic proteins, where he is responsible for antibody generation, a key component of drug discovery, through innovative technologies. Before joining Regeneron, he was at Progenics Pharmaceuticals for 19 years. Previously, Dr. Olson was a scientist at MicroGeneSys and Johnson & Johnson’s RW Johnson Pharmaceutical Research Institute. Dr. Olson received his B.S. in chemical engineering at the University of North Dakota, and his Ph.D. in biochemical engineering from Massachusetts Institute of Technology.
L. Andres Sirulnik, M.D., Ph.D. joined Regeneron in 2020 and serves as senior vice president, translational & clinical sciences, hematology, leading strategic program direction and clinical sciences work for our early- and late-stage oncologic hematology and late-stage non-oncology hematology portfolios. Before joining Regeneron, Dr. Sirulnik was chief medical officer at Merus N.V., a clinical-stage immuno-oncology company. Prior to Merus N.V., he spent a decade at Novartis in various roles of increasing responsibility, ultimately overseeing the clinical strategy for their immuno-oncology portfolio. Dr. Sirulnik is a licensed physician, formerly practicing at Dana-Farber Cancer Institute and Brigham and Women’s Hospital and was a fellow in hematology/oncology at Mount Sinai Health System. He completed his medical residency at North Shore Long Island Jewish (LIJ) Health System and conducted post doctorate work at Columbia University. He received his Ph.D. in medicine and molecular biology from King’s College, University of Cambridge and his M.D. from the University of Buenos Aires.
Randy Soltys, Ph.D., joined Regeneron in 2011 and now serves as senior vice president, drug safety and pharmacometrics, where he is responsible for the toxicology, pathology, preclinical PK/PD and clinical and quantitative pharmacology organizations. Prior to joining Regeneron, he held senior leadership positions in drug safety assessment at Genentech and Bristol-Myers Squibb. Dr. Soltys received his B.S. in microbiology from Rutgers University and his Ph.D. in pharmacology/toxicology jointly from Rutgers and the University of Medicine and Dentistry of New Jersey, and has been board-certified in toxicology.
Neil Stahl, Ph.D., joined Regeneron in 1991 and has served as executive vice president, research and development since January 2015. Dr. Stahl started his career at Regeneron as a staff scientist in discovery research working on cytokine receptor signaling, and he spearheaded the invention and development of Regeneron’s Trap Technology. Prior to joining Regeneron, Dr. Stahl received his B.S. degree from Duke University and his Ph.D. in biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco.
Brian Zambrowicz, Ph.D., joined Regeneron in 2015 and serves as executive vice president, functional genomics and chief, VelociGene® operations. Prior to joining Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as executive vice president and chief scientific officer. Dr. Zambrowicz received his B.S. from the University of Wisconsin-Madison and his Ph.D. from the University of Washington.
Industrial Operations and
Product Supply Leaders
Frederick Austin joined Regeneron in 2012 and serves as senior vice president, quality control, Raheen. Mr. Austin leads a team responsible for Raheen quality control laboratory and contract laboratories functions. Prior to joining Regeneron, Mr. Austin worked for 14 years at Amgen in various roles of increasing responsibility, including assisting in starting operations at the company’s Longmont, Colorado, and Juncos, Puerto Rico sites, and spent time working at both Novartis and Abbott Laboratories. Mr. Austin earned a B.S. from Colorado State University.
Gerald Carreau joined Regeneron in 2008 and serves as senior vice president, commercial scale manufacturing and manufacturing technology. Prior to Regeneron, Mr. Carreau worked at Novartis (formerly Chiron Corporation). He earned his B.S. from Virginia Polytechnic Institute and State University.
Scott Carver, Ph.D., joined Regeneron in 1998 and serves as senior vice president, manufacturing and process sciences. He previously held roles in process development and preclinical manufacturing, clinical manufacturing and manufacturing sciences. Dr. Carver earned his B.S. in chemical engineering from the University of Nevada, Reno and his Ph.D. in chemical engineering from Iowa State University.
Christine Childrose joined Regeneron in 2014 and serves as senior vice president, IOPS human resources and HR Operations. Ms. Childrose leads workforce development to support IOPS’ rapidly growing operations, new fill and finish capabilities and emerging technologies. She oversees global HR systems and processes and is expanding HR operations to support employees in a growing number of countries outside the U.S. Prior to joining Regeneron, Ms. Childrose worked at Albany Molecular Research Inc., and spent almost two decades at General Electric (GE) in positions of increasing responsibility. She earned a B.S. from the University at Albany and is a graduate of GE’s Financial Services Leadership program.
Patrice Gilooly joined Regeneron in 1998 and serves as senior vice president, quality assurance and operations. Ms. Gilooly has held positions of increasing responsibility in validation and quality assurance and operations. Prior to joining Regeneron, she worked at Raytheon Engineers & Construction, Genzyme Corporation and Repligen Corporation. Ms. Gilooly earned a B.S. in biology from the University of Massachusetts.
Jennifer McNay, Ph.D., joined Regeneron in 2000 and serves as senior vice president of chemistry, manufacturing and controls (CMC) regulatory sciences and industrial affairs. She previously held roles at Regeneron in preclinical manufacturing and process development, process sciences and combination products. Prior to joining Regeneron, she worked at Procter and Gamble. Dr. McNay earned her B.S. in chemical engineering from the University of Delaware and her M.S. and Ph.D. in chemical engineering from the University of Virginia.
Niall O’Leary joined Regeneron in 2012 and serves as senior vice president and site head of IOPS Raheen. He has held leadership positions of increasing responsibility in quality, regulatory affairs, program management and manufacturing across biological, small molecule and medical device platforms. Prior to joining Regeneron, Mr. O’Leary has worked as an independent consultant and at Pulmatrix, Alkermes, Organogenesis and Merck Serono. Mr. O’Leary received his B.S. in biotechnology from Dublin City University, Ireland and his MBA from the Williams College of Business at Xavier University in Cincinnati, Ohio.
David Simon has been with Regeneron since 1998 and is the senior vice president of industrial operations and product supply (IOPS) finance & business operations. Prior to his decades at Regeneron, he managed finances at Freihofer Baking Company. He earned his B.S. from Siena College and his MBA from State University of New York at Albany.
Gerald Underwood joined Regeneron in 1995 and serves as senior vice president, technical operations for the global industrial operations & product supply organization. He has held leadership roles in quality, validation, regulatory, internal manufacturing and engineering. Before joining Regeneron, Mr. Underwood worked at Fluor Daniel, the Jacobs Engineering Group and Day Laboratories. He holds a B.S. in Science from the University of California, Davis.
Daniel Van Plew joined Regeneron in 2007 and has served as executive vice president and general manager, industrial operations and product supply since January 2016. From 2006 to 2007, he served as executive vice president, R&D and technical operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, most recently as senior director, Vacaville operations. From 1998 until 2004, he held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his M.S. in chemistry from Penn State University and his MBA from Michigan State University.
Ron Wang, Ph.D., joined Regeneron in 1999 and currently serves as senior vice president of quality control, leading a global function that leverages strategic business partnerships and automation to provide back-up lab capabilities, protect the supply chain and optimize resources and lab capacity. He has held prior positions at Regeneron in quality control and analytical sciences, and prior to joining Regeneron, worked at Abbott Laboratories conducting diagnostic assay R&D, bio-process development and commercial assay kit manufacturing. He completed his post-doctoral studies at the University of Pennsylvania. He received his Ph.D. in biochemistry from the University of Delaware and his MBA from the State University of New York at Albany.
Benjamin Yocum joined Regeneron in 2000 and serves as senior vice president, manufacturing operations. Mr. Yocum’s broad knowledge and expertise in Good Manufacturing Practices (GMP) and processes have contributed to the successful launch of every Regeneron commercial product. In addition to leading manufacturing operations in New York’s capital region, Mr. Yocum’s sphere of influence extends beyond manufacturing to encompass all aspects of our quality culture. Prior to joining Regeneron, Mr. Yocum worked within the Chemistry Department at Seattle Pacific University. He earned a M.S. from University at Albany.
Dr. Bassler has been a director of the company since 2016. She has been the chair of the Department of Molecular Biology and the Squibb Professor in Molecular Biology at Princeton University since 2003 and is a Howard Hughes Medical Institute investigator. Dr. Bassler previously served as the president of the American Society for Microbiology, as well as on the boards for the American Association for the Advancement of Science, the National Science Foundation and the American Academy of Microbiology. She previously served as a director of Kaleido Biosciences, Inc. She is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the Royal Society of London and the American Philosophical Society. She has received many scientific honors, including a MacArthur Foundation Fellowship, the Lounsbery Award, the Shaw Prize for Life Science and Medicine, the Gruber Prize in Genetics and the Wolf Prize in Chemistry and the Canada Gairdner International Award. Dr. Bassler currently serves on the board of directors of Cidara Therapeutics, Inc. and Royalty Pharma plc.
Dr. Brown has been a director of the company since 1991. He serves as the Distinguished Chair in Biomedical Sciences at the University of Texas (UT) Southwestern Medical Center, a position he has held since 1989. He is also a regental professor of molecular genetics and internal medicine and the director of the Erik Jonsson Center for Molecular Genetics at the UT Southwestern Medical Center at Dallas, positions he has held since 1985. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine and the Royal Society of London.
Dr. Coles has been a director of the company since 2017. He served as the president and chief executive officer of CerevelTherapeutics Holdings, Inc., the parent entity of Cerevel Therapeutics, Inc. from 2019 to 2023, and has served as chair of CerevelTherapeutics Holdings, Inc. since 2018 and continues in this role. He has also served as chair and chief executive officer of TRATE Enterprises LLC, a privately held company, since 2013. He is the former chief executive officer of Yumanity Therapeutics, Inc. Dr. Coles is also the former president, chief executive officer and chair of the board of Onyx Pharmaceuticals, Inc., and the former president, chief executive officer, and member of the board of directors of NPS Pharmaceuticals, Inc. He previously held various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated. In addition, he was a former director of Laboratory Corporation of America Holdings, Campus Crest Communities, Inc., CRISPR Therapeutics AG and McKesson Corporation.
Dr. Goldstein has been a director of the company since 1991. He has been a professor of molecular genetics and internal medicine and the chair of the Department of Molecular Genetics at the University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences, the National Academy of Medicine and the Royal Society of London. He also is a member of the boards of trustees of The Rockefeller University and the Howard Hughes Medical Institute. Drs. Goldstein and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988.
Dr. Guarini has been a director of the company since 2023, joining the company after serving as Chief Information Officer of IBM from 2021 to 2023 with specific focus on information technology, data security and artificial intelligence. Prior to assuming her role as CIO, Dr. Guarini served in multiple executive leadership roles at IBM over more than 20 years, including Chief Operating Officer of IBM Research and Vice President of Product Management for IBM Systems. Dr. Guarini has been included on the Top 100 Leader list (#2 in 2022) from Technology Magazine and Forbes’ CIO Next list (2022), and she is a member of the United States Patent & Trademark Office’s National Council for Expanding American Innovation. She earned her Bachelor of Science and Ph.D. in Applied Physics from Yale University and Stanford University, respectively.
Christine A. Poon is lead independent director. She has served on the board of the company since 2010. She is a former executive-in-residence in the Department of Management and Human Resources and former dean and John W. Berry, Sr. Chair in Business at the Max M. Fisher College of Business at The Ohio State University. Prior to joining Fisher, Ms. Poon was vice chair, worldwide chair of pharmaceuticals, member of the executive committee and director at Johnson & Johnson. Prior to joining Johnson & Johnson, Ms. Poon held senior leadership positions at Bristol-Myers Squibb Company, including president of international medicines and president of medical devices. She serves on the boards of directors of Prudential Financial, Inc. and the Sherwin-Williams Company. She is a former member of the supervisory board of Royal Philips Electronics and the board of directors of Decibel Therapeutics, Inc.
Mr. Ryan has been a director of the company since 2003. He is the former chief executive officer and chair of the board of Prudential Financial, Inc. and served as president and chief operating officer of Chase Manhattan Bank from 1990 to 1994. Mr. Ryan managed Chase’s worldwide retail bank between 1984 and 1990. From 2008 until 2013, Mr. Ryan served as a non-executive director of the Royal Bank of Scotland Group plc. From 2009 to 2019, Mr. Ryan served as a director of Citizens Financial Group, Inc.
Leonard S. Schleifer, M.D., Ph.D., founded Regeneron in 1988, and has been a board member and the company’s president and chief executive officer since its inception. He currently serves as board co-chair. He served as chairman of the board from 1990 through 1994. Dr. Schleifer, together with Regeneron’s founding scientist, Dr. Yancopoulos, built and managed the company over the past 35 years. Dr. Schleifer is a licensed physician and is certified in neurology by the American Board of Psychiatry and Neurology.
Mr. Sing has been a director of the company since 1988. He has served as chief executive officer of GanD, Inc. since 2016, and chair of Grace Science, LLC since 2017. Mr. Sing has extensive venture capital and leadership experience in the biotechnology sector and high technology.
Dr. Schenkein has been a director of the company since 2023 and is a General Partner and Co-lead of the Life Sciences team at GV (Google Ventures). Prior to joining GV in 2019, Dr. Schenkein served as Chief Executive Officer for Agios Pharmaceuticals for ten years. He previously served in clinical leadership roles at major biotechnology companies including Senior Vice President, Clinical Hematology/Oncology at Genentech and Senior Vice President, Clinical Research at Millennium Pharmaceuticals. Since 2009, Dr. Schenkein has also served as Adjunct Clinical Professor of Medicine, Hematology/Oncology at Tufts Medical Center. He is currently a Board Member of Prime Medicine, Denali Therapeutics and Agios. Dr. Schenkein earned his M.D. at the State University of New York Upstate Medical School in Syracuse and completed his medical training at the Tufts University School of Medicine.
Dr. Thompson has been a director of the company since 2022. He served as president and chief executive officer of Memorial Sloan Kettering Cancer Center (MSK) and continues to oversee the Craig Thompson Lab, which studies cellular metabolism and its role in disease. Prior to his time at MSK, Dr. Thompson made significant contributions to cancer research as a physician and clinical investigator. He co-founded Agios Pharmaceuticals and also serves as a director of Charles River Laboratories International, Inc. He previously served as a director of Merck & Co., Inc. Dr. Thompson is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation and the Association of American Physicians.
Dr. Yancopoulos joined Dr. Schleifer in 1989 as founding scientist of the company, and together they built and have managed the company since then. Dr. Yancopoulos is currently board co-chair, president and chief scientific officer, and has been a director of the company since 2001. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004, he became a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and/or developer of the nine FDA-approved drugs Regeneron has developed: EYLEA® (aflibercept) Injection, Praluent® (alirocumab), Dupixent® (dupilumab), Kevzara® (sarilumab), Libtayo® (cemiplimab), EvkeezaTM (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn), ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use, as well as Regeneron's foundation technologies, including the TRAP technology, VelociGene® and VelocImmune®.
Dr. Zoghbi has been a director of the company since 2016. Since 1994, she has been a professor in the Departments of Pediatrics, Molecular and Human Genetics, and Neurology and Neuroscience at Baylor College of Medicine. Dr. Zoghbi is the director of the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and is a Howard Hughes Medical Institute investigator. She has been awarded numerous recognitions for her work, including the Breakthrough Prize in Life Sciences, the Gairdner Award, the Brain Prize, and the Kavli Prize in Neuroscience. Dr. Zoghbi is a member of the National Academy of Medicine, National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the National Academy of Inventors.